Antibodies News and Research RSS Feed - Antibodies News and Research

Study provides proof of concept for developing antibodies against human pathogens

Study provides proof of concept for developing antibodies against human pathogens

Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens. [More]
Lithium therapy duration not linked to thyroid effects

Lithium therapy duration not linked to thyroid effects

The risk of altered thyroid function does not increase with duration of lithium treatment in patients with bipolar disorder, research suggests. [More]
Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland. [More]
Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A. [More]
Johns Hopkins researchers develop online tool to speed up creation of new drugs to prevent Ebola virus

Johns Hopkins researchers develop online tool to speed up creation of new drugs to prevent Ebola virus

Johns Hopkins biomedical engineers have developed a free, browser-based online tool that could speed up the creation of new drugs to treat or prevent Ebola virus infections. [More]
Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland. [More]
Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade. [More]
New research may help develop drug for celiac disease

New research may help develop drug for celiac disease

Celiac disease patients suffer from gluten intolerance and must adjust to a life without gluten from food sources like wheat, rye and barley. [More]
Leaders in research hope to uncover promising drugs in pharma libraries, conduct clinical trials

Leaders in research hope to uncover promising drugs in pharma libraries, conduct clinical trials

Drugs for brain diseases such as Alzheimer's, Parkinson's, and motor neurone disease that have stalled in development could be revived thanks to the efforts of a global coalition of non-profit organizations and funders announced today. [More]
'Spillover' of henipaviruses into humans underway, study finds

'Spillover' of henipaviruses into humans underway, study finds

Another family of viruses, deadly in some cases, may have already jumped from fruit bats into humans in Africa, according to a study published today in the journal Nature Communications. The study provides the first, preliminary scientific evidence that "spillover" of henipaviruses into human populations is underway. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Three-day global symposium on Ebola virus, other infectious diseases

Three-day global symposium on Ebola virus, other infectious diseases

The 11th annual International Consortium on Anti-Virals (ICAV) symposium, Infectious Diseases: Global Public-Health Challenges of the Next Decade, will put the challenges posed by several infectious diseases under the microscope, including the Ebola virus, the H7N9 influenza virus, MERS coronavirus and dengue viruses, as well as drug-resistant tuberculosis. [More]
PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma, Inc. (PDL) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]
New vaccination approach can reduce tumor burden, suppress formation of lung metastases

New vaccination approach can reduce tumor burden, suppress formation of lung metastases

In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer. [More]
SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US). [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation. [More]
Study suggests possible link between body fat and risk of immunotherapy toxicity

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. [More]
Sigma-Aldrich acquires Cell Marque

Sigma-Aldrich acquires Cell Marque

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of Rocklin, California based Cell Marque Corporation, an industry-leading provider of in vitro diagnostic (IVD) antibody reagents and kits. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed. [More]